| abstract |
Immunotherapeutic compounds include NK cell engagement domains, NK activation domains, and targeting domains. The targeting domain selectively binds to HER2, HERS or the HER2/HER3 heterodimeric complex and is operably linked to the NK activation domain and the NK cell engagement domain. The compound can be administered to a subject to induce NK-mediated killing of cancer cells, to stimulate the expansion of NK cells in the subject, and/or for the treatment of cancer. |